eFFECTOR Therapeutics, Inc. (EFTR) Income Statement
EFTR 2023 at a glance
Fiscal year ended December 31, 2023 · U.S. dollarsEFTR revenue and net income
EFTR profit margins
EFTR growth rates
to 2023| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −103.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EFTR quarterly EPS vs estimates
eFFECTOR Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters.
EFTR income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue | $0 | $3.6M | $1.4M | $42.0M | $0 |
| Cost of revenue | $111,000 | $53,000 | $24,000 | $160,000 | $307,000 |
| Gross profit | −$111,000 | $3.5M | $1.4M | $42.0M | −$307,000 |
| Research & development | $22.9M | $23.3M | $20.0M | $21.8M | $23.6M |
| Sales, general & admin | $10.9M | $12.6M | $13.4M | $4.3M | $4.7M |
| Total operating expenses | $33.8M | $32.4M | $31.9M | $26.2M | $28.3M |
| Operating income | −$33.8M | −$32.4M | −$31.9M | $15.8M | −$28.6M |
| Interest income | $958,000 | $439,000 | $6,000 | $67,000 | — |
| Interest expense | $2.9M | $2.3M | $1.8M | $1.3M | $1.4M |
| Income before taxes | −$35.8M | −$22.7M | $15.8M | $14.6M | −$29.7M |
| Income taxes | — | −$9.7M | −$24,000 | $351,000 | $135,140 |
| Net income | −$35.8M | −$12.9M | $15.8M | $14.2M | −$29.7M |
| EBITDA | −$32.8M | −$32.4M | −$31.9M | $16.1M | −$28.1M |
| EPS (diluted) | −$16.92 | −$8.47 | $10.58 | $23.74 | — |
| Gross margin | — | 98.5% | 100.0% | 100.0% | — |
| Operating margin | — | −912.0% | −2,230.6% | 37.7% | — |
| Net margin | — | −363.8% | 1,104.8% | 33.8% | — |
| Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $162,000 | $0 | $0 | $0 | $675,000 | $867,000 | $2.0M | $0 | $1.4M | $427,000 | $692,000 |
| Cost of revenue | $28,000 | $30,000 | $26,000 | $27,000 | $28,000 | $27,000 | $18,000 | $3,000 | $5,000 | $4,000 | $6,000 | $4.1M |
| Gross profit | −$28,000 | $132,000 | −$26,000 | −$27,000 | −$28,000 | $648,000 | $849,000 | $2.0M | −$5,000 | $1.4M | $421,000 | −$3.4M |
| Research & development | $5.3M | $6.0M | $5.4M | $4.9M | $6.6M | $6.7M | $6.6M | $6.9M | $3.1M | $6.4M | $5.0M | $4.1M |
| Sales, general & admin | $3.1M | $2.5M | $2.5M | $3.0M | $2.9M | $2.7M | $3.5M | $3.0M | $3.4M | $6.3M | $4.1M | $1.7M |
| Total operating expenses | $8.4M | $8.6M | $7.9M | $7.9M | $9.5M | $8.7M | $9.3M | $7.9M | $6.5M | $12.4M | $8.7M | $5.0M |
| Operating income | −$8.4M | −$8.6M | −$8.3M | −$7.9M | −$9.5M | −$8.7M | −$9.3M | −$7.9M | −$6.5M | $20.0M | −$8.7M | −$5.0M |
| Interest income | $323,000 | $223,000 | $296,000 | $227,000 | $226,000 | $209,000 | $142,000 | $64,000 | $24,000 | $4,000 | $1,000 | $1,000 |
| Interest expense | $749,000 | $758,000 | $750,000 | $722,000 | $689,000 | $697,000 | $570,000 | $505,000 | $478,000 | $490,000 | $488,000 | $480,000 |
| Income before taxes | −$8.8M | −$9.1M | −$8.3M | −$8.4M | −$10.0M | −$9.3M | −$9.6M | −$6.9M | $3.1M | $19.0M | $8.9M | −$5.5M |
| Income taxes | −$15,276 | −$688,000 | −$20,000 | $708,000 | −$239,000 | −$28,000 | $608,000 | $187,000 | −$662,000 | −$32.4M | $778,000 | $449,000 |
| Net income | −$8.8M | −$9.1M | −$8.3M | −$8.4M | −$10.0M | −$9.3M | −$9.6M | −$6.9M | $3.1M | $19.0M | $8.9M | −$5.5M |
| EBITDA | −$8.1M | −$8.3M | −$7.8M | −$7.6M | −$9.3M | −$8.5M | −$9.0M | −$6.4M | $3.6M | $19.5M | $9.4M | −$5.0M |
| EPS (diluted) | −$2.16 | −$3.42 | −$3.25 | −$4.25 | −$6.00 | −$0.22 | −$5.75 | −$4.25 | $1.75 | $0.44 | $10.50 | −$0.37 |
| Gross margin | — | 81.5% | — | — | — | 96.0% | 97.9% | 99.9% | — | 99.7% | 98.6% | −488.4% |
| Operating margin | — | −5,306.8% | — | — | — | −1,292.3% | −1,067.0% | −391.9% | — | 1,400.6% | −2,040.7% | −728.9% |
| Net margin | — | −5,635.2% | — | — | — | −1,371.9% | −1,102.5% | −343.9% | — | 1,332.1% | 2,079.4% | −801.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EFTR's financial statements (latest annual report filed March 26, 2024); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EFTR financial results
eFFECTOR Therapeutics reported no revenue in fiscal year 2023 (ended December 31, 2023). It had a net loss of $35.8 million. Diluted earnings per share came to −$16.92.
See the EFTR stock overview for the latest quote and news, or the EFTR chart for price history and technical indicators.
EFTR income statement FAQ
Does eFFECTOR Therapeutics have revenue?
eFFECTOR Therapeutics reported no revenue for fiscal year 2023, which ended on December 31, 2023.
Is eFFECTOR Therapeutics profitable?
No. eFFECTOR Therapeutics reported a net loss of $35.8 million in fiscal 2023.
How much does eFFECTOR Therapeutics spend on research and development?
eFFECTOR Therapeutics spent $22.9 million on research and development in fiscal 2023.
What are eFFECTOR Therapeutics's earnings per share?
eFFECTOR Therapeutics earned $-16.92 per diluted share in fiscal 2023, compared with $-8.47 a year earlier.
When does eFFECTOR Therapeutics's fiscal year end?
eFFECTOR Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2023 and was filed on March 26, 2024.